Sign Out
Pregnancy: Only limited data on the safety of Fosfomycin treatment during 1st trimester of pregnancy (n=152) are available. These data do not raise any safety signal for teratogenicity so far. Fosfomycin crosses the placenta.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Exelfos should only be used during pregnancy, if clearly necessary.
Breast-feeding: Fosfomycin is excreted in human milk in low quantities. If clearly necessary, a single dose of oral Fosfomycin can be used during breast-feeding.
Fertility: No data in humans are available. In male and female rats oral administration of Fosfomycin up to 1000 mg/kg/d did not impair fertility.
Continue with Google